Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Rosetta Genomics, Tekmira, Bayer CropScience, and More


Title: Compositions and Methods for siRNA Inhibition of HIF-1 Alpha

Patent Number: 8,236,775

Filed: Dec. 3, 2009

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

“RNA interference using small interfering RNAs [that] target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene,” according to the patent's abstract. “As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, particularly in diseases such as diabetic retinopathy, age-related macular degeneration, and many types of cancer.”

Title: microRNAs and Uses Thereof

Patent Number: 8,236,939

Filed: Feb. 8, 2010

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, comprises “polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.”

Title: siRNA Targeting Glucagon Receptor

Patent Number: 8,236,942

Filed: April 13, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for GCGR.”

Title: Compositions and Methods for Silencing Apolipoprotein B

Patent Number: 8,236,943

Filed: June 30, 2010

Lead Inventor: Amy Lee, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention, the patent's abstract states, “provides compositions and methods for the delivery of interfering RNAs that silence apoB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knockdown of apoB at relatively low doses. In addition, the compositions and methods of the ... invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.”

Title: Stress-Related microRNA Molecules and Uses Thereof

Patent Number: 8,237,017

Filed: May 10, 2007

Lead Inventor: Marc Bots, Bayer CropScience

The patent, its abstract states, claims “naturally occurring and synthetic novel stress-related miRNAs … which can be used to modify the stress tolerance of plants.”

Title: Therapeutic and Diagnostic Molecules

Application Number: 20120196925

Filed: June 4, 2010

Lead Inventor: Jennifer Gamble, Centenary Institute of Cancer Medicine and Cell Biology

The invention, the patent application's abstract states, “relates to methods for modulating angiogenesis [by] administering ... one or more miRNA, or precursors, or variants thereof” of a predefined sequence. “Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided.”

Title: Methods and Products for Expression of microRNAs

Application Number: 20120196924

Filed: Dec. 15, 2011

Lead Inventor: Chang-Zheng Chen, Whitehead Institute for Biomedical Research

“The invention relates to microRNAs, methods of producing microRNAs, and methods for using microRNAs,” the patent application's abstract states.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.